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Abstract 
Pharmacological assays carried out in transfected cells have been very useful for 
describing the mechanism of action of cathinone new psychoactive substances (NPS). 
These in vitro characterizations provide fast and reliable information on psychoactive 
substances soon after they emerge for recreational use. Well-investigated comparator 
compounds, such as methamphetamine, 3,4-methylenedioxymethamphetamine, cocaine, 
and lysergic acid diethylamide, should always be included in the characterization to 
enhance the translation of the in vitro data into clinically useful information. We 
classified cathinone NPS according to their pharmacology at monoamine transporters and 
receptors. Cathinone NPS are monoamine uptake inhibitors and most induce transporter-
mediated monoamine efflux with weak to no activity at pre- or postsynaptic receptors. 
Cathinones with a nitrogen-containing pyrrolidine ring emerged as NPS that are 
extremely potent transporter inhibitors but not monoamine releasers. Cathinones exhibit 
clinically relevant differences in relative potencies at serotonin vs. dopamine transporters. 
Additionally, cathinone NPS have more dopaminergic vs. serotonergic properties 
compared with their non-β-keto amphetamine analogs, suggesting more stimulant and 
reinforcing properties. In conclusion, in vitro pharmacological assays in heterologous 
expression systems help to predict the psychoactive and toxicological effects of NPS. 
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1 Introduction 
 In 2014, the European Union Early Warning System (EMCDDA, 2015) reported 
the emergence of 101 new psychoactive substances (NPS). The variety of largely 
unknown NPS is still increasing compared with recent years. With this high number of 
new substances, rapid testing systems are needed to obtain an immediate understanding 
of the mechanism of action of these NPS. Animal studies that utilize behavioral 
paradigms (e.g., to test abuse liability) or neurochemical assessments (e.g., microdialysis 
and voltammetry) to investigate the pharmacology and toxicology of new compounds in 
vivo are relatively expensive and require weeks or months to conduct. Moreover, 
typically only a small number of substances can be tested. In contrast, rapid first 
characterizations of new compounds can be performed within days in a laboratory with a 
set of well-established in vitro assays and using reference data from well-known 
substances. Typically, relatively simple in vitro pharmacological assays with transfected 
cell lines have limited significance in neuroscientific research because more complex 
behavioral and circuit-wide conclusions are required for a comprehensive understanding 
of the mechanism of action of psychoactive substances in the brain. Transfected cell lines 
in heterologous expression systems only reveal the mechanism of action of drugs on 
specific targets that are expressed by the host cell. Therefore, any complex whole-brain 
interactions are lacking. However, to elucidate the pharmacology of a larger set of 
unknown compounds, in vitro assays are highly valuable as the first screening tools. 
Through decades of intensive animal and clinical experimental studies on various 
psychoactive substances (e.g., cocaine, methamphetamine, 3,4-
methylenedioxymethamphetamine [MDMA], and lysergic acid diethylamide [LSD]), 
their mechanism of action in vitro and pharmacological effects in vivo are relatively well 
known, thus allowing translational interpretations of in vitro data on NPS (Liechti, 2015). 
Thus, the clinical pharmacology of NPS can be predicted based on similarities between 
the in vitro mechanisms of action of NPS and well-known and also clinically 
characterized comparator compounds. 
 Our in vitro characterization of cathinone NPS has allowed the rapid 
characterization of these newly emerging substances at known human targets of 
psychoactive compounds (Rickli et al., 2015a; Simmler et al., 2013; Simmler et al., 
2014a). In the context of in vitro and in vivo studies in other laboratories (Baumann et al., 
2012; Baumann et al., 2013; Iversen et al., 2013) and clinical reports, we found that in 
vitro characterizations are consistent with in vivo data but allow for the faster initial 
characterization of larger numbers of newly emerging compounds. Cathinone NPS have 
striking differences in pharmacological potencies to inhibit monoamine transporters, 
which are relevant to appraisals of the type of psychoactivity, abuse liability, and to some 
extent clinical toxicity. For example, in vitro testing has shown that 3,4-
methylenedioxypyrovalerone (MDPV) inhibits the dopamine transporter (DAT) and 
norepinephrine transporter (NET) far more potently when compared with classic 
psychostimulants, such as cocaine and methamphetamine (Baumann et al., 2013; 
Simmler et al., 2013), suggesting that small doses may exert large clinical effects and 
enhance the risk of overdose. This information is essential for users of these compounds 
and clinicians who treat overdose cases. However, pharmacological properties, such as 
bioavailability and blood-brain barrier permeability, are also important for determining 
the potency of a substance in vivo. Additional pharmacological studies are thus needed 
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for a more comprehensive characterization. Overall, in vitro profiling is particularly 
helpful for systematic comparative characterizations of a large number of substances, in 
which basic and rapid information on the compounds’ pharmacological characteristics is 
essential, such as with the current NPS problem. 
 In this article, we discuss the principles of in vitro pharmacological assays that are 
used to characterize the primary mechanisms of action of cathinone NPS. We discuss the 
advantages and limitations of such assays with regard to the rapid emergence of NPS in 
recent years. We also highlight methodological issues and discuss the main 
characteristics of cathinone NPS in these assays. 
 
2 Methods for Studying Transporter and Receptor Pharmacology in Transfected 
Cells 
 Stably transfected cells represent a heterologous expression system in which the 
protein of interest is expressed in a host cell that does not endogenously express the 
respective protein. For the pharmacological profiling of cathinone NPS, the respective 
monoamine transporter or pre- and postsynaptic receptor genes are introduced into 
neutral cell lines (Ramamoorthy et al., 1993; Revel et al., 2011; Tatsumi et al., 1997). 
Human embryonic kidney (HEK) 293 cells are very commonly used for stable 
transfections and subsequent pharmacological assays. For stable transfections, a plasmid 
with the cDNA sequence of the target protein from any species is introduced into the 
cells (Groskreutz & Schenborn, 1997). The co-introduction of a geneticin-resistance gene 
ensures that only transfected cells are maintained in culture (Chaudhary et al., 2012). The 
stable expression of a target protein is not necessarily required for in vitro 
pharmacological assays (Henry et al., 2006), but stable cell lines simplify the workflow 
because the step of transiently transfecting cells before each assay can be omitted. 
Transfected cell cultures are a standard procedure for molecular biology laboratories. 
With recent technological improvements (e.g., CRISPR/Cas9 technology), transfections 
are becoming even easier (Ran et al., 2013). Once stably transfected, the cells express the 
protein in high abundance both in the membrane, which is essential for functional assays, 
and in the cytoplasm (Chamba et al., 2008; Marazziti et al., 2007). For assays that are 
used for investigations of cathinone NPS, only one gene of interest is introduced per cell 
line, thus ensuring selectivity in the pharmacological assessment. Non-transfected cells 
can serve as a control for nonspecific drug action (i.e., nonspecific binding to the cell 
membrane; Ramamoorthy et al., 1993).   
 To comprehensively characterize psychoactive compounds at their typical 
neuronal target sites in vitro, the effects of these compounds on the different 
monoaminergic neurotransmitter uptake transporters and various neurotransmitter G-
protein-coupled receptors need to be determined in a battery of assays. Therefore, 
individual cell lines that overexpress the respective target protein after transfection are 
used to determine binding affinity, uptake transport inhibition, and transporter-mediated 
efflux in separate assay setups. For transporters, uptake inhibition (e.g., in the case of 
cocaine) and the transport-mediated efflux of transmitter (e.g., in the case of most 
amphetamines) are determined in different assays. For the relevant receptors, functional 
assays are performed to determine agonistic or antagonistic properties, including 
information about full or partial agonist effects. Binding affinities at both transporters and 
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receptors are also frequently determined, but functional tests are considered more 
conclusive than binding affinities. The assay principles are described in more detail later 
in this chapter. Briefly, transport assays require a radiolabeled substrate of the 
transporters, usually endogenous neurotransmitters (Ramamoorthy et al., 1993). Through 
quantification of the transported radiolabeled substrates, the inhibition potencies or efflux 
characteristics of a specific substance can be determined. To determine binding affinities, 
a radioligand displacement principle is applied, in which the substance’s ability to 
compete with the radioligand for the binding site is quantified (Maguire et al., 2012). For 
receptor activity, cyclic adenosine monophosphate (cAMP) levels can be quantified 
(Zhang & Xie, 2012). This downstream factor indicates signaling that is induced by G-
protein-coupled receptors, in which cAMP levels increase upon activation of the 
receptors or decrease upon inhibition of the receptors (Tate, 2012). For all of the assays, 
classic enzyme kinetics are the basis for calculating pharmacological determinants (i.e., 
IC50, EC50, and Ki values; Burlingham & Widlanski, 2003; Cheng & Prusoff, 1973).  
 Heterologous expression systems for monoaminergic neurotransmitter 
transporters have been relevant in neuropsychopharmacology research since these 
transporters were first cloned. Transporter-expressing cell lines allow the characterization 
of psychoactive compounds (Tatsumi et al., 1997) and are also a useful tool for 
discovering psychoactive therapeutic drugs (Bang-Andersen et al., 2011). Furthermore, in 
vitro experiments with transfected cells formed the basis for many genetic mutations that 
were later engineered in mice, which now serve for in vivo investigations of psychoactive 
drugs or as preclinical models of mental disorders (Henry et al., 2006; Mazei-Robison et 
al., 2008; Prasad et al., 2005). For example, in vitro experiments allowed the construction 
of a transgenic mouse model with a 5-hydroxytryptamine (5-HT [serotonin]) transporter  
(SERT) mutation for the in vivo assessment of SERT-mediated effects of antidepressants 
or cocaine (Prosser et al., 2014; Thompson et al., 2011) or to shed light on functional 
abnormalities of the DAT variant Val559, which is being investigated as a potential 
mouse model of attention-deficit hyperactivity disorder (Mergy et al., 2014). 
 Today, heterologous expression systems are a relatively simple tool for use in any 
laboratory with basic cell culture and molecular biology setups. Furthermore, once cell 
lines stably express a specific receptor, these lines can be maintained by freezing stocks, 
and such stocks can then be used over decades. One of the greatest strengths of in vitro 
screening assays that use transfected cells is the high selectivity for the pharmacological 
targets of interest. For example, for DAT uptake inhibition, cells that overexpress DAT 
are used, while for SERT inhibition a different cell line overexpressing SERT is used. 
Due to separation of the targets in different runs no unspecific action at the second target 
can affect the result. Furthermore, human proteins can be overexpressed to assess 
pharmacological profiles directly with targets of the human species (Tatsumi et al., 
1997). Species differences could be a concern in ex vivo or in vivo experiments because 
target proteins may exhibit distinct substance recognition between rodents/nonhuman 
primates and humans or show differential expression patterns. For example, the 
antidepressant imipramine is more potent at the human SERT than at the rat SERT, 
whereas cocaine inhibits both rat and human SERT with equal potencies (Barker & 
Blakely, 1996). The most common variant of the respective target is usually expressed in 
NPS screening, but its also feasible to generate cell lines with different variants of human 
transporters or receptors to specifically assess the pharmacological and toxicological 
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effects of psychoactive substances on less common gene variants. While many 
advantages are evident for the use of heterologous expression systems to screen NPS 
pharmacological profiles, there are also limitations and disadvantages compared to 
similar experimental approaches. Synaptosomes or brain slices are frequently used ex 
vivo-preparations to assess the pharmacology of psychoactive substances. In brain slices 
substantial cellular characteristics are still intact, and synaptosomes contain the full 
complement of synaptic proteins and synaptic vesicles (Wilhelm et al., 2014). 
Synaptosomes resemble the natural environment of the site of psychostimulant action 
more than transfected cell lines. Interpretations from experiments in transfected cells are 
limited since they lack elements of the protein machinery of intact neuronal membranes 
that could be critical for certain protein/substance interactions and consequences. 
However, for target-selective assays typically used for the determination of 
pharmacological constants unintended targets have to be pharmacologically blocked in 
synaptosomes (Rothman et al., 2001; Rothman et al., 1993). In this regard, both 
transfected cell lines and ex vivo preparations (e.g., synaptosomes) have their advantages 
and limitations for the screening of NPS pharmacology and should always be kept in 
mind when interpreting results. Nevertheless, pharmacological profiles of NPS assessed 
in transfected cells have largely been in accordance with data obtained from 
synaptosomes.  
 It is self-evident that there are limitations to in vitro screenings with transfected 
cells or ex vivo preparations and various consequences of NPS use can only be assessed 
by in vivo testing, particularly behavior or long-term toxicity. With regards to 
pharmacological profiles, however, we would like to point out that the possibility of 
active metabolites should be considered. Heterologous cell lines for in vitro screenings of 
NPS pharmacology are largely unable to detect the possible contribution of active 
metabolites that could, however, be relevant in vivo. For example, 3,4-
methylenedioxyamphetamine (MDA) is an active metabolite of MDMA and likely 
contributes to the subjective drug experience and toxicity associated with MDMA (de la 
Torre et al., 2000). Cathinone NPS may also have active metabolites that should be taken 
into account in more comprehensive pharmacological substance characterizations. For 
example, β-keto-MDA is a metabolite of methylone (Mueller & Rentsch, 2012) and 
interacts with monoamine transporters similarly to MDA in in vitro tests (Rickli et al., 
2015b). In vitro testing for active metabolites requires knowledge of the metabolic 
pathway and synthesis of possibly active metabolites or the use of cell systems that 
contain metabolic enzymes. To elaborate the metabolites for every single NPS would be a 
very labor-intensive process. In vivo neurochemical studies that utilize microdialysis can 
be performed more easily and may include possible contributing effects of active 
metabolites on neurotransmission. 
 The specific assay setups for uptake and efflux transport assays vary considerably 
between laboratories. In the most widely used experimental setup for in vitro 
pharmacology, transfected cell lines are grown to adherence in well plates or small 
culture dishes. Adherence of the cells allows for the removal of uptake buffer and 
washing with ice-cold buffer to stop substrate transport. However, if timing is an 
essential factor in uptake experiments (which is usually more essential for substrate 
kinetics than for inhibition potencies [IC50 values]), then the possibility of the rapid and 
timely termination of the uptake process is crucial. With suspended synaptosome 
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preparations, the use of a Brandel tissue harvester allows for the timely termination of 24-
96 vials at once. It becomes more difficult when the assay is conducted on adherent cell 
cultures. Even with an automated wash station for cell culture plates, achieving 
satisfactory accuracy to terminate the uptake process can be either challenging or 
impossible. When we established the assay that is currently used in our laboratory, we 
chose to use a silicone-oil-centrifugation method. We perform the uptake assay in cell 
suspensions that are prepared from adherent cells. Centrifuging the cells through a 
silicone oil layer allows for rapid and precise termination of the uptake process and the 
cleaning of cells from the buffer (Torok et al., 1998). Silicone oil is used as a middle 
layer in a tube. In the centrifugation step, the cells but not radioactive uptake buffer 
transfer to the lower layer (consisting of 3 M KOH, which lyses the cells). We have 
found that this method is very reliable and precise, but handling can be more elaborate 
and more difficult than working with adherent cells or synaptosomes. No conclusive 
recommendation has been made for the ideal assay setup. In fact, every laboratory needs 
to establish and validate its own assay setup for transport assays. If the assay follows the 
rules of enzyme kinetics and if reproducibility within the laboratory can be demonstrated, 
then the specific details of the assay are of less concern. 
 Between uptake assays for different pharmacological targets (e.g., SERT vs. DAT 
uptake inhibition), direct comparisons even within a laboratory and setup cannot be 
guaranteed if only IC50 and not Ki values are determined. However, the inclusion of a set 
of comparator compounds (e.g., methamphetamine, MDMA, and cocaine) with widely 
reported pharmacological characteristics should serve to set the standard for comparisons 
of IC50 values between targets. For example, calculating the DAT/SERT ratio for well-
known compounds like MDMA can be the reference for unknown compounds (Baumann 
et al., 2012; Rickli et al., 2015b). This again shows the importance of including well-
known reference compounds in screening and that the value of a study increases 
according to the number of substances that are included. 
 Reproducibility within a laboratory is essential for the extensive characterization 
of multiple compounds. In general, for comparable IC50 values in large screenings within 
one laboratory requires strict adherence to the established protocol since IC50 values  
depend on substrate concentration, in addition to temperature and incubation times. We 
regularly test the reproducibility of IC50 values for our standard compounds and find that 
the values are very consistent across both time and experimenters. This regular validation 
ensures that the data for all substances that are reported from our laboratory can be 
directly compared with our previously reported data. To consider are also fluctuations in 
target protein expression in heterologous expression systems that could account for 
inconsistent IC50 values within one laboratory (Ukairo et al., 2007).  However, if in vitro 
assays are set up with a targeted protein concentration within a linear range in a protein 
concentration vs. substrate transport relationship, moderate changes in cell number used 
for an individual assay or in target protein expression are usually tolerated and do not 
affect the reproducibility of IC50 values within laboratory, always given a linear 
relationship of target protein vs. substrate transport. As a side note, this is in contrast to 
transport kinetics (i.e., Michaelis-Menten kinetics), in which the maximal velocity is 
highly dependent on the expression levels of the transporter. With these considerations 
comparison of IC50 values within one laboratory is unproblematic. For direct comparison 
of pharmacological constants between different laboratories Ki values should be assessed, 
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since IC50 but not Ki values depend significantly on assay conditions (Burlingham & 
Widlanski, 2003). The determination of Ki values is more complex because it requires 
knowledge or assessment of the mode of inhibition (e.g., competitive, noncompetitive, or 
mixed; Burlingham & Widlanski, 2003). Although Ki values would be the best constants 
to determine, the rapid and extensive characterization of the effects of a large set of 
cathinone NPS on multiple targets usually does not allow the labor-intensive 
determination of Ki values. Given these limitations, in vitro screenings assessing IC50 
values are only of value when a large of substances is assessed within one laboratory or if 
well-known comparator compounds are included as reference compounds that allow for 
an interpretation of pharmacological profiles relative to the reference compounds. 
 Different setups for monoamine efflux assays have been described, all resulting in 
similar qualitative characterizations of compounds. Although different setups are valid, 
establishing an efflux assay can be difficult. Efflux can be measured using 
electrophysiological methods (Hilber et al., 2005; Khoshbouei et al., 2003), which allow 
the very reliable determination of transporter-mediated monoamine release and its 
associated currents that are induced by compounds. However, because patch-clamp 
electrophysiology requires specialized recording equipment, we only discuss radiolabeled 
substrate transport assays herein. Rothman et al. (Rothman et al., 2001) reported the use 
of efflux assays with rat synaptosomes, in which synaptosomes were first preloaded to 
steady-state with the radioactive substrate via transporter-mediated uptake. Release was 
then induced without removing the radioactive uptake buffer. Using this method, a high 
signal-to-noise ratio was reported, but efflux potency values could be determined. 
Verrico et al. adapted this protocol for transfected HEK293 cells in suspension (Verrico 
et al., 2007). We initially followed this protocol (Hysek et al., 2012c) but later adapted it 
according to the principles reported by Scholze et al. (Scholze et al., 2000), who used a 
superfusion system. The superfusion system is preferentially used for rodent tissue slices 
that are preloaded with radioactive transporter substrates (Mergy et al., 2014), but it can 
also be adapted for transfected cells (Pifl et al., 1995; Scholze et al., 2000). Transfected 
cells are grown on coverslips and loaded with radioactive substrates. They are then 
moved to superfusion chambers where the cells are constantly superfused with non-
radioactive buffer (Scholze et al., 2000). The advantage of this method is that the 
radioactive substrates that are released are transported away from the cells or tissue 
(Raiteri et al., 1974) so that the reuptake of released substrate should not occur. We 
adapted this principle to our laboratory but used well plates instead of a superfusion 
system. To achieve a similar effect as superfusion with regard to the immediate removal 
of released substrate, we took advantage of the dilution effect. Using a high buffer-to-cell 
ratio, the monoamine substrate that is released by the cells is distributed in a large volume 
of buffer, resulting in negligible extracellular substrate concentrations. To achieve a high 
buffer-to-cell ratio, we used special 24-well plates (XF24, Seahorse Biosciences, North 
Billerica, MA, USA), which fit 1 ml of buffer per well, but the area for cell growth is as 
small as the one from a regular 96-well plate. Therefore, the buffer-to-cell ratio is much 
higher than the one in a standard cell culture 96-well plate or 24-well plate, thus 
providing an optimal assay setup for testing substance-induced monoamine efflux. 
Release is quantified by assessing the monoamine radioactivity that remains in the cells 
after incubation with the test substance and compared with a vehicle control. 
Additionally, radioactivity that is associated with the released monoamine can be 
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measured in the supernatant. In transfected cells, an apparent release of approximately 
20% for pure uptake inhibitors is observed even with the superfusion method, most likely 
because of the high expression levels of transporters that transport nonspecifically 
released monoamines back into the cells (Scholze et al., 2000). Thus, uptake inhibitors 
need to be included as a negative control condition to account for apparent release. 
Apparent release can be lowered if 
3
H-MPP+ is used for DAT and NET instead of the 
endogenous substrates DA and NE, but one caveat is the difference in transport kinetics 
between MPP+ and the endogenous substrates (Johnson et al., 1998). In our hands, 
apparent release was less with our well-plate method than with cells in suspension. 
Nevertheless, we chose to focus on determining qualitative release instead of release 
potencies, which are more difficult to determine. The precise determination of apparent 
release-corrected efflux potencies would require knowledge of the respective apparent 
release percentage for each concentration in the concentration/release curve. This would 
require a perfect match of uptake potencies of the control substance to measure apparent 
efflux and the actually releasing substance, which is practically unfeasible. Therefore, we 
determined release qualitatively by inducing it with high concentrations of a drug to 
determine whether the drug is a releaser and thus a transporter substrate or not.  
 Binding affinity can be determined for any ligand/protein interaction. For binding 
affinity, the ability of a substance to displace a radiolabeled ligand at the receptor or 
transporter is assessed, which requires competition between two compounds at the 
binding site. To assess the mode of action of NPS, binding can be determined for 
receptors and transporters (Simmler et al., 2013; Tatsumi et al., 1997). However, for both 
receptors and transporters, the functional assays are considered to have higher predictive 
validity with regard to in vivo effects. For the transporter, functional information is 
derived from the uptake and efflux assays. Specifically for substances that are releasers 
and thus substrates of the transporters, the binding properties or even the binding sites 
can differ from the radioligand that is to be displaced. Additionally, the substrates are 
transported and thus removed from competition with the radioligand. Binding affinity 
values do not necessarily reflect the functional uptake inhibition potency (Simmler et al., 
2013). This is a common phenomenon for binding studies that use ligands that are also 
transporter substrates because transport of the substrate can alter the apparent binding 
affinity (Marcusson et al., 1986; Nelson & Rudnick, 1979; Talvenheimo et al., 1979). 
Thus, if a substance is a substrate-type releaser, then its binding affinity, when assessed 
by the described displacement assay, is not representative. This discrepancy between 
binding affinities and uptake inhibition potencies can even be used to characterize a 
substance as substrate-type release or pure uptake blocker (Eshleman et al., 1999; 
Rothman et al., 1999). 
 The determination of binding affinity is more common for receptors than for 
transporters. However, it is also important for receptor pharmacology to distinguish 
between functional activity and binding affinity (Zhang & Xie, 2012). The concepts for 
assessing activity and affinity in heterologous expression systems are different. To 
determine binding affinity, only the target protein from the expression is required. 
Therefore, isolated membrane preparations that can be stored in a frozen state are usually 
made from transfected cells. In radioligand displacement assays, the binding affinities of 
compounds at the binding site of the radioligand are determined. Functional information 
with regard to activation or inactivation of a G-protein-coupled receptor can be gained 
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from cAMP measurements in living transfected cells using convenient, commercially 
available kits that do not require radioactivity. The activation of G-protein-coupled 
receptors results in a concentration-dependent increase in cAMP levels, the activation 
potency of which can be determined (EC50 value). Similarly, the activation of G-protein-
coupled receptors can be assessed by measuring intracellular calcium changes (Rickli et 
al., 2015c). With the inclusion of a known full agonist (typically an endogenous ligand) 
in the assay, the maximal efficacy can be determined. Full agonists induce maximal 
efficacy, whereas partial agonists induce only partial efficacy compared to endogenous 
ligands. 
 With regard to the translational relevance of in vitro screenings, setting the data in 
an informative clinical context is essential. Comparisons with well-known psychoactive 
substances inform about the similarity of NPS to these substances with known subjective 
effects, toxicity, and abuse liability. Furthermore, data on the link between 
pharmacological targets and subjective/physiological effects are needed. Several rodent 
and human studies have contributed to our understanding of the roles of DAT, SERT, and 
NET inhibition in the mode of action of psychoactive drugs. In rodents, particularly mice, 
genetic modification allows the elimination of a specific target and assessment of the 
behavioral and molecular impacts of the knockout. Constitutive knockout mouse models 
generally have the limitation of compensatory alterations that can occur, thus resulting in 
distinct phenotypes that are not ideal for finding explicit target-mediated effects (Kalueff 
et al., 2010; Viggiano et al., 2003; Xu et al., 2000). Nevertheless, several knockout 
studies have implicated the DAT and SERT in the actions of psychostimulants. For 
example, SERT knockout mice exhibit greater rewarding effects of cocaine in the 
conditioned place preference paradigm compared with wildtype mice (Sora et al., 2001). 
More sophisticated genetic models with a triple amino acid mutation in the DAT gene 
showed that DAT inhibition is necessary for cocaine-induced conditioned place 
preference (O'Neill et al., 2014) and cocaine-evoked synaptic plasticity (Brown et al., 
2010). Clinical studies that assess pharmacological interactions between a 
psychostimulant and receptor-selective antagonists or well-characterized transporter 
ligands shed light on specific molecular target mediating subjective effects and acute 
toxicity in humans. For example, our laboratory investigated the mode of action of 
MDMA in humans by blocking the NET, SERT, or DAT or combinations thereof (Hysek 
et al., 2011; Hysek et al., 2012c; Hysek et al., 2014; Liechti et al., 2000; Schmid et al., 
2014; Schmid et al., 2015). These studies showed that NET and α1-adrenergic stimulation 
are crucially involved in MDMA-induced sympathomimetic activation, including 
elevations of blood pressure and body temperature (Hysek et al., 2012a; Hysek et al., 
2013; Hysek et al., 2011; Schmid et al., 2015) and that the SERT-mediated release of 5-
HT is involved in the subjective entactogenic/empathogenic effects of MDMA (Hysek et 
al., 2012b; Hysek et al., 2012c; Liechti et al., 2000). Interactions with the DAT and 
activation of the DA system are generally considered responsible for the reinforcing and 
addictive properties of a substance (Howell & Wilcox, 2002). Accordingly, NPS that 
mostly interact with the SERT can be expected to produce more empathogenic MDMA-
like effects, in contrast to NPS that mostly interact with the NET and DAT and are thus 
expected to produce more stimulant-type effects and addiction similar to 
methamphetamine (Liechti, 2015; Simmler et al., 2013). Additionally, we noted that 
substances, such as MDMA, that primarily release endogenous monoamines via the 
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transporter may have a shorter duration of action despite having a long plasma half-life 
(Hysek et al., 2012c) than substances that only inhibit a transporter (e.g., pyrovalerone 
cathinones; Derungs et al., 2011) or interact with postsynaptic receptors (e.g., 
hallucinogens; Dolder et al., 2015; Rickli et al., 2015c).  
 In vivo studies in rodents and humans increase our knowledge of the effects and 
toxicity that are related to individual targets that mediate the complex actions of 
psychostimulants and help predict the toxicity of NPS. Dissecting the clinical roles of 
different neurotransmitter systems and attributing specific effects to specific targets or 
pharmacological profiles (e.g., DAT/SERT ratio; Liechti, 2015; Simmler et al., 2013) 
support the meaningful translation of in vitro NPS pharmacology to expected subjective 
effects and toxicity in humans. Newer techniques, such as optogenetic approaches, for 
dissecting brain circuitry or sophisticated transgenic animal models without 
compensatory alterations that can isolate target-mediated effects in vivo will continue to 
shape our understanding of psychoactive drug actions with regard to specific targets, 
which will also impact interpretations of the in vitro pharmacology of NPS. 
 
3 Effects on Cathinone Analogs on Transporter-Mediated Uptake 
 All cathinone NPS inhibit transporter-mediated monoaminergic uptake but with 
different selectivity and relative potencies. The precise profile of relative DAT, SERT, 
and NET inhibition potencies likely determines the different experiences that are 
described by drug users. In the screening from our laboratory, most cathinone NPS are 
potent NET inhibitors, with uptake inhibition potencies in the submicromolar range 
(Table 1). N,N-dimethylcathinone, ethylone, methedrone, and 4-methylethcathinone are 
the exceptions with NET inhibition IC50 in the low micromolar range. High potency for 
NET inhibition relative to DAT and SERT were also reported from other laboratories 
(Eshleman et al., 2013; Iversen et al., 2013; Rosenauer et al., 2013), but with less 
prominent fold-shifts compared to DAT inhibition. This likely arises from different assay 
conditions that determine the IC50 values. However, the general high inhibition potency 
of NET for most cathinones NPS are consistent across laboratories. Drug-induced 
increases in NE markedly contribute to the psychostimulation of a drug and 
sympathomimetic toxicity (Hysek et al., 2011; Hysek et al., 2012c). We compared the 
common recreational doses that are taken in a single drug session and uptake inhibition 
potencies at the NET, SERT, or DAT and found that the recreational doses correlated 
mainly with NET inhibition potencies (Simmler et al., 2013). This is in agreement with 
Rothman et al. (2001) who found a linear correlation between release-induction potency 
in synaptosomes and oral doses producing Therefore, the in vitro inhibition potency at 
NET best predicts clinical potency and the doses that are likely to be used recreationally. 
 Significant differences in DAT and SERT inhibition potencies among cathinone 
NPS are evident (Iversen et al., 2013; Simmler et al., 2013; Simmler et al., 2014a). Many 
cathinone NPS are potent DAT inhibitors that are comparable to methamphetamine or 
cocaine, and some cathinone NPS are weak DAT inhibitors that are more comparable to 
MDMA. In our assays, methamphetamine and cocaine, which are well-known 
psychostimulants that act on the DAT, exhibit DAT inhibition potencies (IC50 values) 
around 1 µM. Many pyrovalerone cathinones are extremely potent DAT inhibitors. The 
most popular pyrovalerone cathinone, MDPV, is 30-times more potent in inhibiting the 
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DAT in heterologous expression systems than cocaine (Eshleman et al., 2013; Simmler et 
al., 2013). Similarly in synaptosomes 40 – 50-fold differences in DAT inhibition potency 
between MDPV and cocaine were reported (Baumann et al., 2013). MDPV is also called 
“super coke,” and small doses may have strong and long-lasting effects because of its 
high potency and pure uptake inhibition (Ross et al., 2012). Severe toxicity and even 
deaths have resulted from the recreational use of this substance (Borek & Holstege, 2012; 
Murray et al., 2012). To avoid such cases, warnings could be issued for extremely potent 
substances like MDPV as soon as they emerge as recreationally used substances. 
Therefore, testing newly emerged NPS in in vitro pharmacological screenings as fast as 
possible is highly important to detect substances with high potencies at monoaminergic 
targets that are relevant to stimulant or other psychotropic actions.  
 Inhibition of the SERT is generally less represented among the cathinone 
derivatives but is characteristic for such substances as benzofuranes (Rickli et al., 2015b), 
aminoindanes, benzylpiperazines (Simmler et al., 2014b), and ring/para-substituted 
amphetamines (Rickli et al., 2015a), which have MDMA-like psychoactive properties. 
Compared with the serotonergic drug MDMA, only naphyrone among the cathinone NPS 
is equally potent in inhibiting the SERT (Iversen et al., 2013; Simmler et al., 2013). 
However, methedrone has a similar DAT/SERT inhibition ratio to MDMA, thus 
predicting a similar effect profile to MDMA, in addition to predicting high risk of 
hyperthermia because of its similarity to para-methoxy-amphetamine (Liechti, 2015; 
Simmler et al., 2014a). Other cathinone NPS inhibit the SERT with lower potencies, 
resulting in relatively more dopaminergic properties, or their SERT inhibition is 
negligible. 
 Ideally, the SERT inhibition potency of substances is set relative to their DAT 
inhibition. Relative activity at the DAT vs. SERT can serve as an indicator of the abuse 
liability of a psychoactive substance because potent SERT activity relative to DAT 
activity can be protective against the abuse of a drug (Bauer et al., 2013; Schindler et al., 
2015; Wee et al., 2005). Substances with potent SERT inhibition are less reinforcing than 
substances with low SERT vs. DAT activity (Bauer et al., 2013; Rothman & Baumann, 
2006; Wee et al., 2005). Using uptake inhibition potencies, we calculated DAT/SERT 
ratios (IC50,SERT/IC50,DAT). Note that the calculation with the reciprocal formula 
IC50,SERT/IC50,DAT results in high DAT/SERT ratios for substances that inhibit DAT more 
potently (lower IC50 value) than SERT (higher IC50 value) and vice versa. In our hands, 
where cocaine has a DAT/SERT ratio of ~1, substances with a DAT/SERT ratio > 1 can 
be considered to have high abuse liability. Substances with a DAT/SERT ratio close to 
that of MDMA (0.1) likely have lower abuse liability. For example, we predicted 
particularly high abuse potential for MDPV based on its high DAT/SERT inhibition ratio 
(Simmler et al., 2013). Animal studies and clinical observations confirmed the potent 
reinforcing and rewarding properties of MDPV, confirming in vitro study-based 
predictions of abuse potential (Watterson et al., 2014; Watterson & Olive, 2014). 
 For some cathinone NPS in our screening studies, we determined the profile of 
respective structural amphetamine analogs that lack the β-keto group (Rickli et al., 
2015b; Simmler et al., 2013; Simmler et al., 2014a). Adding a β-keto group to MDMA to 
form methylone resulted in a higher DAT/SERT ratio and thus higher predicted abuse 
liability. The shift in the DAT/SERT inhibition ratio that results from the addition of a β-
keto group was less pronounced for amphetamines with an already high DAT/SERT 
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inhibition ratio, such as methamphetamine. Notably, a small change in the molecular 
structure of some amphetamines can result in a significantly different pharmacological 
profile. 
 
4 Effects of Cathinones on Transporter-Mediated Efflux 
 Substances that inhibit monoamine transporters are either pure uptake inhibitors 
or releasers (Rothman et al., 2001). If they are monoamine releasers, then they induce 
transporter-mediated efflux, which should not be confused with exocytotic calcium-
dependent vesicular monoamine release. Transporter-mediated efflux occurs when drugs 
act as substrates of the transporters (Sulzer et al., 2005). As substrates, the substances are 
transported into the cell. Because amphetamine analogs, such as MDMA and 
methamphetamine, are releasers (Rothman et al., 2001; Rudnick & Wall, 1992), it is of 
interest to characterize cathinone NPS as releasers or pure uptake inhibitors. All releasers 
or substrates, including the endogenous substrates (i.e., DA, NE, and 5-HT), present 
uptake inhibition properties because of competition for transport (Rothman et al., 2001). 
Therefore, uptake assays cannot determine whether a substance is an inhibitor or a 
substrate releaser, but separate efflux assays can determine whether a drug is a releaser or 
pure uptake inhibitor. Interestingly, pyrovalerone cathinones are pure uptake inhibitors 
(Table 2), although they are amphetamine-type substances. Most other cathinone NPS are 
releasers like their amphetamine analogs (Table 2). 
 We distinguish monoamine-releasing substances from pure monoamine uptake 
inhibitors, but the impact of release vs. pure uptake inhibition on psychoactive effects is 
unclear and likely less relevant than the DAT/SERT inhibition ratio (Liechti, 2015). This 
distinction is less relevant for subjective and stimulant effects than for cellular toxicity. 
Because release-inducing substances enter nerve terminals via transporters, they are more 
likely to exert intracellular effects and toxicity compared with pure uptake inhibitors 
(Sulzer et al., 2005). Typically, releasers act on vesicular monoamine transporters and 
deplete vesicles, which can have short- or long-term toxic consequences (Steinkellner et 
al., 2011). 
 With the large numbers of NPS reported in the recent years, there is need for a 
classification of NPS. NPS can be classified by their chemical structures. For example, 
Hill et al. (2011) classified MDMA as ring-substituted methylenedioxyphenethylamine, 
mephedrone as beta-ketonated amphetamine, and MDPV as beta-ketonated substituted 
methylenedioxyphenylethylamine. A structural classification is very useful for an 
audience with an interest in the chemical structure of NPS. An audience with a clinical 
focus might mainly be interested in anticipated subjective effects and toxicology. A 
classification according to pharmacological profiles are likely more meaningful for 
clinicians than chemical structures, particularly also since structural similarities not 
necessarily result in comparable pharmacological profiles. In our NPS screenings, we 
classify cathinone derivatives according to the similarity of their in vitro profile to 
methamphetamine, cocaine, and MDMA (Liechti, 2015; Simmler et al., 2013). 
DAT/NET-selective pyrovalerone cathinones represent a separate group since they are 
extremely potent inhibitors. Importantly, small structural changes can markedly alter the 
pharmacological profile of substances, sometimes in an unpredicted manner, resulting in 
different psychoactive and toxicological effects. For example methylone, the ß-keto 
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analog of MDMA, presents a prominent increase in DAT/SERT ratio, suggesting a higher 
abuse potential of methylone compared to MDMA (Baumann et al., 2012; Simmler et al., 
2013). Classification according to pharmacology may thus be more conclusive as a 
reference for clinical applications than structural analogies. 
 
5 Drug Interactions with G-Protein-Coupled Receptors 
 In addition to transporter pharmacology, assessing receptor interactions is 
necessary for a comprehensive pharmacological characterization of psychoactive 
substances. The major implications would be for the assessment of any hallucinogenic 
properties of NPS. LSD has high affinity for the 5-HT2A receptor (Nichols, 2004; Rickli 
et al., 2015c), which is associated with its hallucinogenic properties. Other drugs with 
potent 5-HT2A activity have been shown to substitute for LSD in drug-discrimination 
studies (Eshleman et al., 2014). In vitro activity at the 5-HT2A receptor is a good predictor 
of possible hallucinogenic effects and is likely the most relevant receptor/NPS interaction 
that is assessed in in vitro screening, particularly for potentially hallucinogenic 
compounds (Rickli et al., 2015c). The activation of DA D1 receptors but not D2 receptors 
might be sufficient for a substance to be rewarding (Caine et al., 2007). Noradrenergic 
receptors are involved in sympathomimetic toxicity, leading to vasoconstriction, 
hyperthermia, increased blood pressure, and increased heart rate (Hysek et al., 2012a; 
Hysek et al., 2013). 
 The main targets of amphetamine analogs are typically monoamine transporters, 
but some substances have weak affinity for monoamine receptors. However, it is 
questionable if direct receptor affinity contributes markedly to the overall drug effect of 
substances that foremost are transporter inhibitors. The rise in extracellular monoamine 
concentration that is evoked by a drug’s effects at the transporters results in 
neurotransmitter binding to postsynaptic receptors, which might cause that direct 
agonism has only negligible contribution to the overall drug effect. Direct antagonistic 
receptor activation might, to some extent, counteract neurotransmitter binding at 
postsynaptic receptors. We and others did not find any cathinones or amphetamines with 
relevant affinity at D1, D2, or D3 receptors (Iversen et al., 2013; Rickli et al., 2015a; 
Simmler et al., 2013; Simmler et al., 2014a). However, some cathinone analogs exhibit 
weak affinity for 5-HT2A or 5-HT2C receptors and are low-potency 5-HT2A antagonists 
(Eshleman et al., 2013). Compared with hallucinogens that exert their psychoactive 
effects mainly via 5-HT receptors (e.g., the NPS benzodifuran 2C-B-Fly or novel N-2-
methoxybenzyl-derivatives), with receptor binding values in the submicromolar range 
(Rickli et al., 2015b; Rickli et al., 2015c), the weak binding affinities of cathinones at 
these targets are likely irrelevant. 
 In our pharmacological characterization of NPS, we also include the trace amine-
associated receptor 1 (TAAR1; Rickli et al., 2015a; Simmler et al., 2013; Simmler et al., 
2016; Simmler et al., 2014a). Methamphetamine and other amphetamine-type drugs have 
been shown to activate the TAAR1, and the TAAR1 could be a target for the 
pharmacological treatment of addiction (Jing & Li, 2015). Substance-mediated agonist 
effects at the TAAR1 may reduce the stimulant properties of MDMA and 
methamphetamine (Achat-Mendes et al., 2012; Di Cara et al., 2011). In contrast, 
cathinone NPS do not present affinity for the TAAR1 and may thus have more stimulant-
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like effects and be more addictive than their amphetamine analogs because of the lack of 
this TAAR1-mediated “auto-inhibition,” in addition to their greater dopaminergic 
properties. This could be relevant for experiments conducted in rodents. In humans, 
however, direct affinity of psychoactive substances is probably negligible since in general 
no or only weak activation of the human TAAR1 by psychostimulants is evident from in 
vitro screenings (Simmler et al., 2016). Nevertheless, TAAR1 presents a promising target 
that could be highly relevant for psychostimulant treatment.  
 
6 Summary 
 NPS continue to emerge and are recreationally used without much knowledge 
about their pharmacology or toxicology. In vitro characterizations of psychoactive 
compounds that utilize transfected cell lines are useful for gaining fast and translationally 
important information on cathinone NPS. The in vitro pharmacological profiles of 
cathinone NPS have predicted considerable abuse liability of these drugs and identified 
pyrovalerone cathinones with extremely high potencies for DAT inhibition. Small 
structural changes, such as the β-keto group in the amphetamine-basic structure, can 
substantially change the pharmacological profile of substances with regard to their 
potency and relative activity at different monoaminergic targets.  
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Tables and Figures 
 
Table 1: Uptake inhibition potencies of cathinone NPS and the respective non-β-keto analogues.
NET DAT SERT NET DAT SERT
Cathinone-analogs IC50 (µM) (95% CI) IC50 (µM) (95% CI) IC50 (µM) (95% CI) Amphetamine-analogs IC50 (µM) (95% CI) IC50 (µM) (95% CI) IC50 (µM) (95% CI) Values published in
4-Bromomethcathinone 0.41 (0.30-0.57) 5.6 (2.7-12) 2.2 (1.7-2.8) (3)
Buphedrone 0.65 (0.51-0.81) 4.24 (3.3-5.5) 70 (2-2700) (2)
Buthylone 2.02 (1.5-2.7) 2.90 (2.5-3.4) 6.22 (4.3-9.0) MBDB 2.80 (1.9-4.1) 22 (20-26) 2.04 (1.4-3.0) (1)
Cathinone 0.199 (0.15-0.26) 14.0 (10-20) >100 Amphetamine 0.094 (0.06-0.14) 1.30 (0.83-2.0) >10 (1)
N,N -Dimethylcathinone 7.71 (5-12) 27 (21-36) > 500 (2)
Ethcathinone 0.44 (0.34-0.56) 5.00 (3.7-6.8) 48 (4-529) N-Ethylamphetamine 0.20 (0.15-0.27) 5.86 (4.8-7.1) 8.77 (6-13) (2)
4-Ethylmethcathinone 2.5 (1.7-3.7) 31 (13-72) 4.3 (3.2-5.9) (3)
Ethylone 2.54 (2.0-3.2) 5.68 (4.9-6.5) 4.46 (3.8-5.2) MDEA 1.02 (0.78-1.3) 9.3 (8.0-11) 1.27 (0.93-1.7) (1)
Flephedrone 0.246 (0.16-0.37) 6.35 (4.2-9.5) >10 4-Fluoromethamphetamine 0.22 (0.14-0.35) 7.7 (2.5-24) 8.7 (3.8-20) (1),(3)
3-Fluoromethcathinone 0.19 (0.13-0.29) 1.7 (1.0-3.0) 56 (7-472) (2)
β-keto MDA 1.6 (1.1-2.3) 14 (10-18) 21 (15-28) MDA 0.42 (0.3-0.6) 20.5 (20.3-20.6) 4.9 (3.5-6.8) (4)
MDPBP 0.16 (0.11-0.24) 0.11 (0.07-0.16) 15 (5.4-39) (3)
MDPPP 0.97 (0.62-1.5) 0.53 (0.27-1.1) 75 (49-114) (3)
MDPV 0.044 (0.03-0.07) 0.031 (0.03-0.04) 9.30 (6.8-12.8) (1)
Mephedrone 0.254 (0.22-0.30) 3.31 (2.6-4.2) 4.64 (3.7-5.9) (1)
Methcathinone 0.085 (0.06-0.17) 1.12 (0.83-1.5) >10 Methamphetamine 0.064 (0.04-0.09) 1.05 (0.74-1.5) >10 (1)
Methedrone 2.24 (1.4-3.5) 35 (15-79) 4.73 (3.2-6.9) PMMA 1.20 (0.75-1.8) 49 (18-135) 1.77 (1.1-2.9) (2)
4-Methylethcathinone 2.23 (1.6-3.2) 4.28 (3.4-5.4) 7.93 (3.5-18) (2)
Methylone 0.542 (0.39-0.75) 4.82 (3.8-6.1) 15.5 (10-26) MDMA 0.447 (0.33-0.60) 17 (12-24) 1.36 (1.0-2.0) (1)
Naphyrone 0.25 (0.20-0.32) 0.47 (0.40-0.55) 0.96 (0.85-1.09) (1)
Pentedrone 0.61 (0.52-0.72) 2.50 (2.0-3.2) 135 (5-3700) (2)
Pentylone 0.99 (0.72-1.4) 1.34 (1.0-1.7) 8.37 (5.4-13) (2)
Pyrovalerone 0.043 (0.03-0.06) 0.035 (0.03-0.04) 13.0 (10.8-15.8) (1)
α-PVP 0.02 (0.01-0.03) 0.04 (0.01-0.1) > 100 (3)
(1) Simmler et al. , 2013, Br J Pharmacol (3) Rickli et al.,  2015, Eur Neuropsychopharmacol
(2) Simmler et al. , 2014, Neuropharmacology (4) Rickli et al. , 2015, Br J Pharmacol
Pharmacology cathinone-analogs Pharmacology amphetamine-analogs
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Table 2: Qualitative characterization of cathinone NPS and the respective non-β-keto 
analogues as releasers at NET, DAT, and SERT.         
 
Cathinone-analogs 
  
Amphetamine-analogs 
 
 
    
 
   
 
Cathinone-analogs 
NE 
efflux 
DA 
efflux 
5-HT 
efflux  
Amphetamine-analogs 
NE efflux DA efflux 
5-
HT 
effl
ux 
Values 
published 
in 
                    
4-
Bromomethcathinone 
yes yes no 
     
(3) 
Buphedrone yes no no 
     
(2) 
Buthylone NA no yes 
 
MBDB NA no yes (1) 
Cathinone NA yes no 
 
Amphetamine yes yes yes (1),(3) 
N,N-
Dimethylcathinone 
no no no 
     
(2) 
Ethcathinone yes no yes 
 
N-Ethylamphetamine yes yes yes (2) 
4-Ethylmethcathinone yes yes yes 
     
(3) 
Ethylone NA no yes 
 
MDEA NA no yes (1) 
Flephedrone yes yes yes* 
 
4-
Fluoromethamphetamine 
yes yes yes (1),(3) 
3-
Fluoromethcathinone 
yes yes yes 
     
(2) 
β-keto MDA yes no yes 
 
MDA yes yes yes (4) 
MDPBP no no no 
     
(3) 
MDPPP no no no 
     
(3) 
MDPV no no no 
     
(1),(3) 
Mephedrone yes yes yes 
     
(1),(3) 
Methcathinone yes yes yes* 
 
Methamphetamine yes yes yes (1),(3) 
Methedrone yes no yes 
 
PMMA yes yes yes (2) 
4-Methylethcathinone no no yes 
     
(2) 
Methylone NA no yes 
 
MDMA yes yes yes (1),(3) 
Naphyrone no no no 
     
(1),(3) 
Pentedrone no no no 
     
(2) 
Pentylone no no yes 
     
(2) 
Pyrovalerone no no no 
     
(1),(3) 
α-PVP no no no 
     
(3) 
                    
NA) not assessed 
  
(1) Simmler et al., 2013, Br J Pharmacol 
(3) Rickli et al., 2015, Eur 
Neuropsychopharmacol 
  *) Not significant in Rickli et al., 2015, Eur 
Neuropsychopharmacol 
(2) Simmler et al., 2014, 
Neuropharmacology 
(4) Rickli et al., 2015, Br J 
Pharmacol 
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Figure 1 
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Figure 2 
 
